Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae

• Published in: Annals of clinical microbiology and antimicrobials 2017-03, Vol.16 (1), p.18-18, Article 18
• Main Authors: Xu, Liangfei, Sun, Xiaoxi, Ma, Xiaoling
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Antibiotics; beta-Lactam Resistance; Carbapenem-resistant; Carbapenemase; Carbapenems - pharmacology; CRKP; Drug resistance; Drug therapy; E coli; Enzymes; Global Health; Humans; Infections; Intensive care; K. pneumoniae; Klebsiella; Klebsiella Infections - microbiology; Klebsiella Infections - mortality; Klebsiella pneumoniae - drug effects; Klebsiella pneumoniae - isolation & purification; Literature reviews; Meta-analysis; Mortality; Patients; Pneumonia; Studies; Transplantation; Urinary tract; Urinary tract infections
• ISSN: 1476-0711; 1476-0711
• DOI: 10.1186/s12941-017-0191-3

Carbapenem resistant K. pneumoniae (CRKP) has aroused widespread attention owing to its very limited therapeutic options, and this strain has increased rapidly in recent years. Although it is accepted that drug resistance is associated with increased mortality in general, but some other studies found no such relationship. To estimate mortality of patients infected with CRKP in general and analyze factors for mortality of this infection, thus, we conducted this systematic review and meta-analysis. A systematic literature review of relevant studies published until December 2015 was conducted. We selected and assessed articles reporting mortality of patients infected with CRKP. Pooled mortality was 42.14% among 2462 patients infected with CRKP versus 21.16% in those infected with carbapenem-susceptible K. pneumoniae (CSKP). The mortality of patients with bloodstream infection (BSI) or urinary tract infection was 54.30 and 13.52%, respectively, and 48.9 and 43.13% in patients admitted to the intensive care unit (ICU) or who underwent solid organ transplantation (SOT). Mortality was 47.66% in patients infected with K. pneumoniae carbapenemase-producing K. pneumoniae and 46.71% in those infected with VIM-producing K. pneumoniae. Geographically, mortality reported in studies from North America, South America, Europe, and Asia was 33.24, 46.71, 50.06, and 44.82%, respectively. Our study suggests that patients infected with CRKP have higher mortality than those infected with CSKP, especially in association with BSI, ICU admission, or SOT. We also considered that patients' survival has a close relationship with their physical condition. Our results imply that attention should be paid to CRKP infection, and that strict infection control measures and new antibiotics are required to protect against CRKP infection.